Management of adult vitiligo: approved topical JAK inhibitor and standard therapies - PubMed
5 days ago
- #dermatology
- #vitiligo
- #JAK-inhibitor
- Vitiligo is a chronic autoimmune depigmenting disorder.
- Ruxolitinib 1.5% cream is the only FDA-approved therapy for vitiligo.
- Standard off-label treatments include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phototherapy (NB-UVB or excimer devices).
- Systemic therapies may be used in specific cases but have heterogeneous evidence.
- Treatment selection should be personalized based on disease activity, extent, location, and patient preferences.
- Ruxolitinib showed superior efficacy in phase II-III RCTs compared to vehicles.
- Potent TCS, TCI, and targeted phototherapy are effective for localized vitiligo.